tbuckley/cabot-search huggingface dataset:
Dual IGF-I/II–Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth
Authors: Jin Gao, Jon W. Chesebrough, Susan A. Cartlidge, Sally-Ann Ricketts, Leonard Incognito, Margaret Veldman-Jones, David C. Blakey, Mohammad Tabrizi, Bahija Jallal, Pamela A. Trail, Steven Coats, Klaus Bosslet, Yong S. Chang
Journal: Cancer Research (2011)

Insulin-like growth factors (IGF), IGF-I and IGF-II, are small polypeptides involved in regulating cell proliferation, survival, differentiation, and transformation. IGF activities are mediated through binding and activation of IGF-1R or insulin receptor isoform A (IR-A). The role of the IGF-1R pathway in promoting tumor growth and survival is well documented. Overexpression of IGF-II and IR-A is reported in multiple types of cancer and is proposed as a potential mechanism for cancer cells to develop resistance to IGF-1R-targeting therapy. MEDI-573 is a fully human antibody that neutralizes both IGF-I and IGF-II and inhibits IGF signaling through both the IGF-1R and IR-A pathways. Here, we show that MEDI-573 blocks the binding of IGF-I and IGF-II to IGF-1R or IR-A, leading to the inhibition of IGF-induced signaling pathways and cell proliferation. MEDI-573 significantly inhibited the in vivo growth of IGF-I- or IGF-II-driven tumors. Pharmacodynamic analysis demonstrated inhibition of IGF-1R phosphorylation in tumors in mice dosed with MEDI-573, indicating that the antitumor activity is mediated via inhibition of IGF-1R signaling pathways. Finally, MEDI-573 significantly decreased (18)F-fluorodeoxyglucose ((18)F-FDG) uptake in IGF-driven tumor models, highlighting the potential utility of (18)F-FDG-PET as a noninvasive pharmacodynamic readout for evaluating the use of MEDI-573 in the clinic. Taken together, these results demonstrate that the inhibition of IGF-I and IGF-II ligands by MEDI-573 results in potent antitumor activity and offers an effective approach to selectively target both the IGF-1R and IR-A signaling pathways.
Improving Physician Well-Being—Reply
Authors: Colin P. West, Liselotte N. Dyrbye, Tait D. Shanafelt
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
A Comparison Between Alternative and Trade Name Glucose Test Strips
Authors: M James Lenhard, G Stephen De Cherney, Raelene E Maser, Bernardine C Patten, Jennifer Kubik
Journal: Diabetes Care (1995)

OBJECTIVE To determine the reliability of seven different alternative glucose test strips manufactured for use with three different glucose meters. RESEARCH DESIGN AND METHODS Venous blood samples were obtained from volunteers to test trade name glucose test strips on the manufacturers' glucose meters (One Touch II, Glucometer II, and Glucometer III), and the remainder of each sample was used for laboratory determination of blood glucose levels. In addition to the trade name test strips, Quick Check and First Choice test strips were tested on all meters, and Biotel test strips were also tested on the Glucometer III. RESULTS In linear regression analysis, the R2 ranged from 0.84 to 0.97 for the test strips compared with plasma glucose values. The test strips with the highest accuracy and precision at all ranges of blood glucose levels were the One Touch II and Glucometer III trade name strips and the Quick Check and First Choice alternative strips for the One Touch II glucose meter and the First Choice alternative strip for the Glucometer II. Subgroup analysis based on ranges of blood glucose values, however, revealed that the alternative strips were not as accurate as the trade name test strips, with the exception of the First Choice alternative test strip for the Glucometer II. All of the trade name test strips were more precise than the alternative test strips designed for the individual meters. CONCLUSIONS Alternative glucose test strips can be used to predict the actual laboratory blood glucose values but are generally not as accurate or precise as the trade name test strips.
Hemodynamic Effects of Isoproterenol Infusion in Patients with Normal and Diseased Mitral Valves
Authors: ROBERT E. WHALEN, ALLAN I. COHEN, ROBERT G. SUMNER, HENRY D. MCINTOSH
Journal: Circulation (1963)

Hemodynamic effects of isoproterenol infusion were studied in 26 patients with and without mitral valve disease undergoing combined right and left heart catheterization. The heart rate and cardiac output rose while the left ventricular end-diastolic pressure, pulmonary vascular resistance, and total peripheral resistance fell, regardless of the status of the mitral valve. Infusion produced little change in the mean arterial blood pressure and the diastolic filling period per minute. While the mean left atrial and pulmonary artery pressures fell in patients with normal or insufficient valves, these pressures rose in patients with mitral stenosis. Stroke volume tended to rise in all patients but those with mitral stenosis. In patients with combined mitral stenosis and insufficiency the insufficiency appeared to modify the hemodynamic response associated with mitral stenosis. The presence of a lowered end-diastolic pressure in the left ventricle and an increased pressure in the left atrium in patients with stenosis suggests that isoproterenol has a direct or reflex effect on the left ventricle during diastole.
Relationship of Cerebrospinal Fluid Pleocytosis to Recovery of ECHO 9 Virus
Authors: Te-Wen Chang, Louis Weinstein
Journal: JAMA (1962)

A SMALL NUMRER of the patients with meningitis caused by enteric cytopathogenic human orphan (ECHO) 9 virus studied in this clinic in 1958 were noted to have spinal fluid which was normal in all respects but from which the virus was isolated. Similar experiences have been recorded with the same disease by Sabin and coworkers and by McAllister and associates, and with infections of the nervous system caused by ECHO 6, Type 1 poliomyelitis, and Coxsackie A-9 viruses. The data obtained in 1958 were reexamined in an attempt to determine whether any factors which might be related to or responsible for this phenomenon could be demonstrated. It is the purpose of this communication to present the results of this analysis and to point out that there appeared to be an inverse relationship between the number of cells in the cerebrospinal fluid and the frequency with which ECHO 9 virus was
OCULAR COMPLICATIONS OF INJURIES TO THE HEAD.
Authors: JOHN T. CARPENTER
Journal: JAMA (1901)

The clinical fact that blindness may follow blows on the head is by no means new, but until Berlin, in 1879, cleared up the pathology of these cases, their etiology was clouded in vague conjecture. Beer attributed the amaurosis following head injuries to the reflex influence of the supraorbital nerve. The result of anatomic studies, however, by Berlin, Leber, and Von Hőlder, proved that direct damage to the optic nerve or its sheath in the foramen opticum by fracture of the orbital wall frequently occurred. Von Hölder, in his cases studied postmortem, found fracture of the orbital vault in 90 per cent., while the optic canal was implicated in about 60 per cent. There were hemorrhages into the nerve sheath in about 48 per cent. of the 88 cases. The line of fracture in some instances passed through both foramina. In Treves' "System of Surgery," illustrations show the line of
Abstract P2-16-08: LORHA: Efficacy and safety of 1st-line trastuzumab based treatment, administered for at least 3 years, in patients with HER2-positive metastatic or locally advanced breast cancer - Final results
Authors: J-M Ferrero, C Levy, J-P Spano, P Beuzeboc, D Coeffic, L Arnould, A Lortholary, F André, F Mayer
Journal: Cancer Research (2013)

Abstract Background: A subset of patients with HER2-positive metastatic (mBC) or locally advanced breast cancer (aBC) respond to 1st line trastuzumab-based regimen and have no disease progression for several years. These long-term responders were evaluated in daily practice in the LORHA study. Patients and disease characteristics were presented earlier (ESMO 2012). Material and Methods: Lorha is an ambispective, multicenter, non-interventional study conducted in 57 centers in France. Eligible patients were women aged more than 18 years with HER2-positive mBC or aBC treated with 1st line trastuzumab and progression-free for at least 3 years after starting trastuzumab. The primary objective was to describe clinical and tumor characteristics. Secondary objectives included Progression Free Survival (PFS), Overall Survival (OS), treatment administration and safety. Patients were followed-up for 12 months. Final results are presented here. Results: Overall 160 patients were enrolled; 128 were eligible for efficacy analysis and 154 for safety analysis. Median age was 61 years [34-95]. Tumor characteristics were: invasive ductal carcinoma for 112 patients (88%), positive hormonal receptors in 72 patients (58%). At initial diagnosis, 91 patients (71%) had stage I - II tumors and 37 patients (29%) had de novo mBC or aBC. The main metastatic localizations were bone, liver, lymph nodes and lung in 54 (43%), 44 (35%), 25 (20%) and 24 (19%) patients, respectively. Median 1st line trastuzumab treatment duration was 4.5 years [0.8 - 12.1]. Trastuzumab 1st line was associated with a taxane-based chemotherapy in 104/128 patients (81%). Median PFS was 6.4 years [5.7; - Not reached] and median overall survival was not reached. At 1-year follow-up, 23 deaths (15% of patients) were reported, mainly due to disease progression (21 patients - 91%). No toxic death related to trastuzumab was observed. Grade 3-4 adverse events reported prospectively occurred in 14 patients (10%) and included two patients (1.2%) with grade 3-4 cardiac events related to trastuzumab (congestive cardiac failure and left ventricular dysfunction), both events resolved, one with sequelae. Conclusions: Final results of the LORHA study show that long responding patients receiving first-line trastuzumab-based treatment for aBC or mBC in daily practice, can reach a median PFS of more than 6 years, combined with an acceptable safety profile. Median overall survival is still not reached. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-08.
"Spot" Reduction of Fat
Authors: KENNETH V. SCHWARTZ
Journal: Annals of Internal Medicine (1971)

Letters, Comments, and Corrections1 August 1971"Spot" Reduction of FatKENNETH V. SCHWARTZKENNETH V. SCHWARTZAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-75-2-316_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: I would like to reply to the article of Drs. Gwinup, Chelvam, and Steinberg in the March issue (Ann Intern Med 74:408-411, 1971). The thesis of "spot reduction" expressed by Mayer (1) assumes that removal of excessive fat in an area will be enhanced by exercise in that area. I do not feel that very active tennis players provide a good model for this concept.Any tennis player or watcher will readily agree that the nonracket arm is hardly a limp overweight extremity; in fact it is used extensively for throwing balls up, balance, and so forth....Reference1. MAYER J: Overweight, Causes, Cost and Control. New York, Prentice-Hall, Inc., 1968, p. 198 Google Scholar1. GWINUP G: Energetics: Your key to Weight Control. Los Angeles, Sherbourne Press; New York, Bantam Books; 1970 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: KENNETH V. SCHWARTZAffiliations: Cornell University Medical College New York, N.Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1971Volume 75, Issue 2 Page: 316-316 Keywords Exercise Fats Overweight ePublished: 1 December 2008 Issue Published: 1 August 1971 PDF downloadLoading ...
Bone Marrow Transplantation Shows Superior Atheroprotective Effects of Gene Therapy With Apolipoprotein A-I Milano Compared With Wild-Type Apolipoprotein A-I in Hyperlipidemic Mice
Authors: Lai Wang, Behrooz G. Sharifi, Theresa Pan, Lei Song, Ada Yukht, Prediman K. Shah
Journal: Journal of the American College of Cardiology (2006)
Dermatitis Exfoliativa Following Arsphenamine Therapy
Authors: Maurice J. Costello, Simeon Landy
Journal: New England Journal of Medicine (1945)

DURING the course of each year, a number of patients suffering from dermatitis exfoliativa caused by the arsphenamines are treated in the dermatologic wards of Bellevue Hospital. Most of these patients have been treated for syphilis by private physicians, hospital clinics or public-health services in New York City. The 50 cases reported herein were observed at Bellevue Hospital between the years 1937 and 1942, showing that the dreaded postarsphenamine dermatitis is not rare even in the present period of antisyphilitic therapy. These patients were studied in the dermatologic wards from their admission until they were well enough to leave the . . .
305 TREATMENT-INDUCED ANEMIA PREDICTS SVR AMONG ALL HCV-GENOTYPES TREATED WITH PEG-IFNα-2B AND RIBAVIRIN: MARKED DIFFERENCES BETWEEN FEMALE AND MALE
Authors: G. Teuber, S. Mauss, E. Zehnter, M.P. Manns, T. Dahhan, S. Kaiser, U. Meyer, T. Witthöft, B. Möller, N. Dikopoulos, J. Brack, M. Bilzer, G. Tossing, D. Hüppe
Journal: Journal of Hepatology (2010)
Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic
Authors: L Heuft-Dorenbosch, R Landewe, R Weijers, H Houben, S van der Linden, P Jacobs, D van der Heijde
Journal: Annals of the Rheumatic Diseases (2006)

To describe how patients presenting with inflammatory back pain (IBP) of short duration can be classified by different sets of classification criteria for spondyloarthritis (SpA) and ankylosing spondylitis, and which clinical and imaging features are of discernible importance.68 patients with IBP of a maximum of 2 years' duration were included in the early spondyloarthritis cohort. Detailed history, clinical examination and imaging of sacroiliac joints by plain radiography and magnetic resonance imaging (MRI) were obtained. The Berlin criteria set for SpA that has a prominent place for MRI and human leucocyte antigen B27 was used to quantify the relative contribution of MRI in classifying SpA.14 of the 68 patients had ankylosing spondylitis according to the modified New York criteria, 57 patients fulfilled the European Spondylarthropathy Study Group (ESSG) criteria for SpA, 48 patients fulfilled the Amor criteria for SpA (43 patients fulfilled both criteria sets) and 44 patients fulfilled the Berlin criteria for SpA. Only four patients did not fulfil any criteria set; 36 patients fulfilled ESSG, Amor and Berlin criteria. The 14 patients with ankylosing spondylitis fulfilled all three SpA criteria sets.Among our selected cohort of patients with early IBP, the prevalence of SpA according to three different criteria sets is high. The ESSG criteria were the most sensitive, followed by the Amor criteria and the Berlin criteria. The modified New York criteria for ankylosing spondylitis appeared to be the most specific. In this cohort, the contribution of MRI and human leucocyte antigen B27 to purely clinical criteria in making a diagnosis of axial SpA was limited.
Elimination of Measles
Authors: Edward N. Brandt
Journal: JAMA (1982)

To the Editor.—  The elimination of measles as an indigenous disease in this country seems now to be within our reach. By the time this letter is in print, we may have seen at least one week in which no cases of indigenous measles were reported in the United States.  We could not have arrived at this point in our campaign to eliminate measles without the strong support and cooperation ofThe Journalreaders. My purposes in writing are to acknowledge that support—to bring my colleagues up to date on the status of the campaign and to ask for their continued help in the months ahead as we work to make the elimination of measles a permanent reality.  During the past two decades, we have reduced the occurrence of this once common childhood disease from 500,000 cases a year to, last year, just more than 3,000 cases. In the first
Localized toxic pustuloderma associated with nimesulide therapy confirmed by patch testing
Authors: S. Lateo, M.J. Boffa
Journal: British Journal of Dermatology (2002)

Journal Article Localized toxic pustuloderma associated with nimesulide therapy confirmed by patch testing Get access S. Lateo, S. Lateo Department of Dermatology, Sir Paul Boffa Hospital, Floriana VLT 14, Malta Dr Stephanie Lateo, c/o Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, U.K. E‐mail: slateo@hotmail.com Search for other works by this author on: Oxford Academic Google Scholar M.J. Boffa M.J. Boffa Department of Dermatology, Sir Paul Boffa Hospital, Floriana VLT 14, Malta Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 147, Issue 3, 1 September 2002, Page 624, https://doi.org/10.1046/j.1365-2133.2002.488512.x Published: 01 September 2002
Bndothelin-l expression is not altered in necrobiosis lipoidica and granuloma annulare
Authors: N.P. Burrows, F. Abadia Molina, G. Terenghi, J.M. Polak, R. Russel Jones
Journal: British Journal of Dermatology (1994)

Journal Article Bndothelin‐l expression is not altered in necrobiosis lipoidica and granuloma annulare Get access N.P. Burrows, N.P. Burrows Department of Dermatology, Hammersmith Hospital, Du Cane Road, London W120NN, U.K. Search for other works by this author on: Oxford Academic Google Scholar F. Abadia Molina, F. Abadia Molina Department of Histochemistry, Hammersmith Hospital, Du Cane Road, London W120NN, U.K. Search for other works by this author on: Oxford Academic Google Scholar G. Terenghi, G. Terenghi Department of Histochemistry, Hammersmith Hospital, Du Cane Road, London W120NN, U.K. Search for other works by this author on: Oxford Academic Google Scholar J.M. Polak, J.M. Polak Department of Histochemistry, Hammersmith Hospital, Du Cane Road, London W120NN, U.K. Search for other works by this author on: Oxford Academic Google Scholar R. Russel Jones R. Russel Jones Department of Dermatology, Hammersmith Hospital, Du Cane Road, London W120NN, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 130, Issue 6, 1 June 1994, Page 799, https://doi.org/10.1111/j.1365-2133.1994.tb03426.x Published: 01 June 1994
Communicating Gastric-Subphrenic Abscess Proven by Combined Technetium-99m Pertechnetate and Sulfur Colloid Imaging
Authors: ALLEN J. COHEN, ROBERT BRIDGES, SCOTT J. ROWEN
Journal: Clinical Nuclear Medicine (1987)

When confusion exists on an upper Gl series as to whether a cavity communicating with a postoperative stomach is indeed an abscess or distorted stomach, combined pertechnetate and sulfur colloid scintigraphy may aid in clarification.
The Effects of Tibolone in Older Postmenopausal Women
Authors: Steven R. Cummings, Bruce Ettinger, Pierre D. Delmas, Peter Kenemans, Victoria Stathopoulos, Pierre Verweij, Mirjam Mol-Arts, Lenus Kloosterboer, Lori Mosca, Claus Christiansen, John Bilezikian, Eduardo Mario Kerzberg, Susan Johnson, Jose Zanchetta, Diederich E. Grobbee, Wilfried Seifert, Richard Eastell
Journal: New England Journal of Medicine (2008)

Tibolone has estrogenic, progestogenic, and androgenic effects. Although tibolone prevents bone loss, its effects on fractures, breast cancer, and cardiovascular disease are uncertain.In this randomized study, we assigned 4538 women, who were between the ages of 60 and 85 years and had a bone mineral density T score of -2.5 or less at the hip or spine or a T score of -2.0 or less and radiologic evidence of a vertebral fracture, to receive once-daily tibolone (at a dose of 1.25 mg) or placebo. Annual spine radiographs were used to assess for vertebral fracture. Rates of cardiovascular events and breast cancer were adjudicated by expert panels.During a median of 34 months of treatment, the tibolone group, as compared with the placebo group, had a decreased risk of vertebral fracture, with 70 cases versus 126 cases per 1000 person-years (relative hazard, 0.55; 95% confidence interval [CI], 0.41 to 0.74; P<0.001), and a decreased risk of nonvertebral fracture, with 122 cases versus 166 cases per 1000 person-years (relative hazard, 0.74; 95% CI, 0.58 to 0.93; P=0.01). The tibolone group also had a decreased risk of invasive breast cancer (relative hazard, 0.32; 95% CI, 0.13 to 0.80; P=0.02) and colon cancer (relative hazard, 0.31; 95% CI, 0.10 to 0.96; P=0.04). However, the tibolone group had an increased risk of stroke (relative hazard, 2.19; 95% CI, 1.14 to 4.23; P=0.02), for which the study was stopped in February 2006 at the recommendation of the data and safety monitoring board. There were no significant differences in the risk of either coronary heart disease or venous thromboembolism between the two groups.Tibolone reduced the risk of fracture and breast cancer and possibly colon cancer but increased the risk of stroke in older women with osteoporosis. (ClinicalTrials.gov number, NCT00519857.)
Clinical implications of myocardial perfusion status assessed by myocardial blush after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial
Authors: Costantino O. Costantini, Alexandra J. Lansky, Kazuyuki Shirai, Ecaterina Cristea, Cristina Brestowski, Steve Slack, Martin Fahy, Cindy L. Grines, John D. Carroll, Stuckey Thomas, Giulio Guagliumi, Barry Rutherford, Mark Turco, David Mathias, Martin B. Leon, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2003)
Royal Society of Medicine
Authors: Dermatological Section
Journal: British Journal of Dermatology (1910)

Journal Article Royal Society of Medicine Get access Dermatological Section Dermatological Section Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 22, Issue 9, 1 September 1910, Pages 293–297, https://doi.org/10.1111/j.1365-2133.1910.tb16645.x Published: 01 September 1910